Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
34.84
-0.72 (-2.02%)
Sep 26, 2025, 4:08 PM HKT
-2.02%
Market Cap210.92B
Revenue (ttm)14.45B
Net Income (ttm)5.24B
Shares Out6.05B
EPS (ttm)0.88
PE Ratio39.59
Forward PE36.51
Dividend0.34 (0.97%)
Ex-Dividend DateSep 22, 2025
Volume6,480,647
Average Volume13,436,604
Open35.02
Previous Close35.56
Day's Range34.60 - 35.54
52-Week Range15.96 - 39.76
Beta0.60
RSI44.40
Earnings DateNov 18, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]

Sector Healthcare
Founded 1995
Employees 8,989
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3692
Full Company Profile

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.